Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses
File(s)1-s2.0-S0168365916307453-main.pdf (1.31 MB)
Published version
Author(s)
Type
Journal Article
Abstract
The generation of effective levels of antigen-specific immunity at the mucosal sites of pathogen entry is a key goal for vaccinologists. We explored topical vaginal application as an approach to initiate local antigen-specific immunity, enhance previously existing systemic immunity or re-target responses to the mucosae. To deliver a protein vaccine formulation to the vaginal mucosal surface, we used a novel vaginal ring device comprising a silicone elastomer body into which three freeze-dried, rod-shaped, hydroxypropylmethylcellulose inserts were incorporated. Each rod contained recombinant HIV-1 CN54gp140 protein (167 μg) ± R848 (167 μg) adjuvant. The inserts were loaded into cavities within each ring such that only the ends of the inserts were initially exposed.
Sheep received a prime-boost vaccination regime comprising intramuscular injection of 100 μg CN54gp140 + 200 μg R848 followed by three successive ring applications of one week duration and separated by one month intervals. Other sheep received only the ring devices without intramuscular priming. Serum and vaginal mucosal fluids were sampled every two weeks and analysed by CN54gp140 ELISA and antigen-specific B cells were measured by flow cytometry at necropsy. Vaccine antigen-specific serum antibody responses were detected in both the intramuscularly-primed and vaginal mucosally-primed groups. Those animals that received only vaginal vaccinations had identical IgG but superior IgA responses. Analysis revealed that all animals exhibited mucosal antigen-specific IgG and IgA with the IgA responses 30-fold greater than systemic levels. Importantly, very high numbers of antigen-specific B cells were detected in local genital draining lymph nodes.
We have elicited local genital antigen-specific immune responses after topical application of an adjuvanted antigen formulation within a novel vaginal ring vaccine release device. This regimen and delivery method elicited high levels of antigen-specific mucosal IgA and large numbers of local antigen-reactive B cells, both likely essential for effective mucosal protection.
Sheep received a prime-boost vaccination regime comprising intramuscular injection of 100 μg CN54gp140 + 200 μg R848 followed by three successive ring applications of one week duration and separated by one month intervals. Other sheep received only the ring devices without intramuscular priming. Serum and vaginal mucosal fluids were sampled every two weeks and analysed by CN54gp140 ELISA and antigen-specific B cells were measured by flow cytometry at necropsy. Vaccine antigen-specific serum antibody responses were detected in both the intramuscularly-primed and vaginal mucosally-primed groups. Those animals that received only vaginal vaccinations had identical IgG but superior IgA responses. Analysis revealed that all animals exhibited mucosal antigen-specific IgG and IgA with the IgA responses 30-fold greater than systemic levels. Importantly, very high numbers of antigen-specific B cells were detected in local genital draining lymph nodes.
We have elicited local genital antigen-specific immune responses after topical application of an adjuvanted antigen formulation within a novel vaginal ring vaccine release device. This regimen and delivery method elicited high levels of antigen-specific mucosal IgA and large numbers of local antigen-reactive B cells, both likely essential for effective mucosal protection.
Date Issued
2017-01-21
Date Acceptance
2017-01-10
Citation
Journal of Controlled Release, 2017, 249, pp.74-83
ISSN
1873-4995
Publisher
Elsevier
Start Page
74
End Page
83
Journal / Book Title
Journal of Controlled Release
Volume
249
Copyright Statement
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)
(http://creativecommons.org/licenses/by/4.0/)
Sponsor
Bill & Melinda Gates Foundation
Dormeur Investment Service Ltd
Grant Number
OPP1084580
WMND_P50379
Subjects
Science & Technology
Physical Sciences
Life Sciences & Biomedicine
Chemistry, Multidisciplinary
Pharmacology & Pharmacy
Chemistry
TOXIN B-SUBUNIT
CONTRACEPTIVE VAGINAL RINGS
CHOLERA-TOXIN
ANTIBODY-RESPONSES
GENITAL-TRACT
WOMEN
INDUCTION
INFLUENZA
ADJUVANTS
AGONIST
0903 Biomedical Engineering
1115 Pharmacology And Pharmaceutical Sciences
Publication Status
Published